UTHEALTH HOUSTON CCTS BIOBANK VARIABLE LIST

Similar documents
Supplementary Appendix

4. Which survey program does your facility use to get your program designated by the state?

Chemistry Reference Ranges and Critical Values

Chemistry Reference Ranges and Critical Values

SMARTool clinical and biohumoral results. Chiara Caselli IFC-CNR

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Tables of Normal Values (As of February 2005)

Performance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

Supplementary Appendix

APPENDIX F: CASE REPORT FORM

Condition/Procedure Measure Compliance Criteria Reference Attribution Method

SUPPLEMENTAL MATERIAL

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:

Wellness: Concepts and Applications 8 th Edition Anspaugh, Hamrick, Rosato

Supplementary Online Content

Quality Measures MIPS CV Specific

Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use

Acute coronary syndrome. Dr LM Murray Chemical Pathology Block SA

(For items 1-12, each question specifies mark one or mark all that apply.)

Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with

Multiphasic Blood Analysis

ARMYDA-RECAPTURE (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) trial

Reeju Manandhar, Chaofeng Sun. Original article

Medical History Form. Part 1. Administrative Information

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Cardiac Pathophysiology

CLINICAL PROCESS IMPROVEMENT INITIATIVE (CPII) EFFICIENCY REPORT EXPLANATION January 4, 2016

Hamilton Regional Laboratory Medicine Program

C-Reactive Protein and Your Heart

Index. Note: Page numbers of article titles are in boldface type.

Patient-Centered Primary Care Scorecard Measures

Supplement materials:

ANNUAL HEALTH CHECKUP BASIC HEALTH PACKAGE

DO NOT SUBMIT OR FAX THIS PAGE TO COR F M L DD MM YY

Cardiovascular Disease

The ESC Registry on Chronic Ischemic Coronary Disease

10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor

BC Biomedical Laboratories Adult Reference Ranges

Cardiovascular Disorders. Heart Disorders. Diagnostic Tests for CV Function. Bio 375. Pathophysiology

New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.

Anticoagulants and Head Injuries. Asaad Shujaa,MD,FRCPC,FAAEM Assistant Professor,weill Corneal Medicne Senior Consultant,HMC Qatar

THE CARDIOVASCULAR SYSTEM-PART 2

Functional Blood Chemistry & CBC Analysis

Cardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.

Jordan M. Garrison, MD FACS, FASMBS

Program Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name

FastTest. You ve read the book now test yourself

Hamilton Regional Laboratory Medicine Program

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors

Test Result Reference Range Flag

was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr..

Consensus Core Set: Cardiovascular Measures Version 1.0

Quality Payment Program: Cardiology Specialty Measure Set

Clinical Significance of Aldosterone Levels and Low Grade Inflammation in Patients with Coronary Vasospasm

Summary of Research and Writing Activities In Cardiovascular Disease

Results of Ischemic Heart Disease

Cardiovascular Nursing Practice: A Comprehensive Resource Manual and Study Guide for Clinical Nurses 2 nd Edition

CRC 431 Special procedures Bill Pruitt, MBA, CPFT, RRT, AE-C Cardiorespiratory Care University of South Alabama

Diagnosis and Management of Acute Myocardial Infarction

V. Roldán, F. Marín, B. Muiña, E. Jover, C. Muñoz-Esparza, M. Valdés, V. Vicente, GYH. Lip

SUPPLEMENTAL MATERIAL

Genetic Studies of Abdominal Aortic Aneurysms David J. Carey, PhD Weis Center for Research Geisinger Clinic

Quality Payment Program: Cardiology Specialty Measure Set

1. What is the preferred method of anticoagulating a high-risk cardiac patient on chronic warfarin therapy. anticoagulation can be continued,

DICOM Correction Item

Supplementary Online Content

2013 Hypertension Measure Group Patient Visit Form

BASIC METABOLIC PANEL

Measurement Name Beta-Blocker Therapy Prior Myocardial Infarction (MI)

Yes No Unknown. Major Infection Information

Supplementary Material to Mayer et al. A comparative cohort study on personalised

ADULT TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) TELEMETRY BED TRANSFER ORDERS 1 of 4

Current Treatment Of Ischemic Heart Disease In the United States: An Overview. By Dr Gary Mo

GRADING CRITERIA for CMS Regulated Analytes

Coronary Artery Disease Clinical Practice Guidelines

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Peri-operative Troponin Measurements - Pathophysiology and Prognosis

Short Communication Effect of Atorvastatin on E.C.G changes in Coronary artery disease Singh H 1, Gupta A 2, Bajaj VK 3, Gill BS 4, Singh J 5

CARDIAC REHABILITATION PROGRAMME:- MEDICATION

Lab Values Explained. working at full strength. Other possible causes of an elevated BUN include dehydration and heart failure.

Specific Panels. Celiac disease panel. Pancreas Panel:

Routine Clinic Lab Studies

Chapter 4: Cardiovascular Disease in Patients with CKD

Clinical Practice Guideline

TYPE II MI. KC ACDIS LOCAL CHAPTER March 8, 2016

CHAPTER-I MYOCARDIAL INFARCTION

Heart Disease in Women. Charlotte A. Lee, M.D., DBIM, FLMI

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

2010 ACLS Guidelines. Primary goals of therapy for patients

Appendix: ACC/AHA and ESC practice guidelines

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

including prevention, healthy lifestyle behaviors, populations at risk & disparities (age, race/ ethnicity, gender, geographic & socioeconomic)

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

NORMAL LABORATORY VALUES FOR CHILDREN

Transcription:

Please check the requested variables:, and/or. Obtained at Initial Hospital Recruitment Demographics: Age Gender Marital Status Ethnicity Race Height (inches) Weight (pounds) Main language spoken Socioeconomic Characteristics: Education Job Type Life Habits/Behaviors: Physical Activity Nutrition Alcohol Consumption Smoking/Tobacco Use Medical/Health Information: Diagnoses Discharge Diagnoses - ICD9 codes Disease History: Stroke Coronary Disease Acute Myocardial Infarction (AMI): AMI Men age 50 AMI Women age 55 *Electronic Health Record Page 1 BiobankVariableList.xlsx

Please check the requested variables:, and/or. Known conditions associated with AMI: Malignancies Drug use (cocaine, etc.) Hypercoagulable disease (Factor V Leinden, etc) Thromboembolic events: Deep venous thrombosis Pulmonary embolism Mesenteric ischemia Acute Limb Ischema Stroke or Transient Ischemic Attack Diabetes Hypertension Hypercholesterolemia Rheumatologic Disease Renal failure Thyroid problems Prior Stable Coronary Artery Disease Prior Coronary Disease Coronary Disease Risk Congenital Coronary Disease Seizures Loss of Consciousness Cancer: Body location Year of diagnosis Type of Treatment Other Coronary Conditions Depressed/Sad in past year Diagnosed or treated for depression Women s Health: Post menopausal Obtained at Initial Hospital Recruitment *Electronic Health Record Page 2 BiobankVariableList.xlsx

Please check the requested variables:, and/or. Obtained at Initial Hospital Recruitment Familial Disease History: Biological Mother/Father, First Degree Siblings: Stroke AMI Family history (1 st degree relative of patient with premature Coronary Artery Disease (CAD)): AMI prior age 50 in male or 55 in female relatives Percutaneous coronary intervention prior age 50 in male or 55 in female relatives Coronary Artery Bypass Grafting prior age 50 in male or 55 in female relatives Family Dyslipidemias Diagnosis of Familial Hypercholesterolemia Cancer: Type/ Location of cancer Age diagnosed Events Prior to Hospital Recruitment: Prior AMI Prior Aneurysm Prior Congestive Heart Failure Procedures Prior to Hospital Recruitment: Coronary Angioplasty Coronary Artery Bypass Graft Coronary Stent Cardiac Catheterization Procedures: Coronary Artery Bypass Graft Coronary Angioplasty Cardiac Catheterization Peripheral vascular disease Coronary Valve surgery *Electronic Health Record Page 3 BiobankVariableList.xlsx

Please check the requested variables:, and/or. Obtained at Initial Hospital Recruitment Aortic Aneurysm surgery Peripheral vascular disease/vascular surgery Percutaneous Transluminal Coronary Angioplasty Coronary Stent Medications: Acetylsalicylic Acid Beta blocker ACE Inhibitor Plavix HMG Co-reductase inhibitor Estrogen Hormones COUMADIN DIGITALIS AntiCoagulant Selective serotonin reuptake inhibitors Nitrates Vasodilator Calcium Channel Blockers Cardiac Glycoside Persantine Anti Arhytmic Hypolipidemic Diuretic Statin Antiplatelet inhibitors (GPIIb/IIIa) Angiotensin II Receptor Blocker Combined ARBS Combined Ace Inhibitor *Electronic Health Record Page 4 BiobankVariableList.xlsx

Please check the requested variables:, and/or. Values: ALBUMIN APTT BUN CALCIUM CHOLESTEROL CK (CPK) CK-MB (CPK-MB) CREATININE CRP (C-REACT.PROTEIN FIBRINOGEN GLUCOSE HCT HDL CHOLESTEROL HEMATOCRIT (HCT) HEMOGLOBIN (HGB) HEMOGLOBIN A1C HOMOCYSTEINE, BLOOD INR LDL CHOLESTEROL LIPIDS/CORONARY RISK MAGNESIUM MYOGLOBIN, SERUM PHOSPHORUS PLATELET COUNT POTASSIUM PROTEIN,TOTAL SERUM PT PTT RBC SEDIMENTATION RATE Obtained at Initial Hospital Recruitment *Electronic Health Record Page 5 BiobankVariableList.xlsx

Please check the requested variables:, and/or. SODIUM TRIGLYCERIDE TROPONIN T URIC ACID WBC Genomic : Single Nucleotide Polymorphism ABO_rs495828 APOC1_rs4420638 CRP_rs2808629 DARC_rs12075 F5_rs9332575 GCKR_rs1260326 GCKR_rs780093 HNF1A_rs1183910 ICAM1_rs1799969a ICAM1_rs5498a ICAM4_rs3093030 ICAM5_rs885743 IL1F10_rs13409360 IL1F10_rs6734238 IL6R_rs4129267 IL6R_rs4537545 KIF6_rs20455 LOC100131131_rs1030023 MRPL4_rs17000211 MYH15_rs3900940 MYOF_rs701877 RAVER1_rs1045384 Obtained at Initial Hospital Recruitment *Electronic Health Record Page 6 BiobankVariableList.xlsx

Please check the requested variables:, and/or. SALL1_rs1965024 SELP_rs2076074 SELP_rs2235302 SELP_rs3917854a SELP_rs6136a SLC6A4_rs2020934 SLC6A4_rs2020936 SLC6A4_rs4251417 SLC6A4_rs6354 VAMP8_rs1010 CDKN2BAS_26505812_10 LPA_25930271_10 SLC29A3_rs12256138 TIMELESS_rs7486220 CACNA1C_rs2239108 HTR2A_rs3125 VCAM1_rs3917010 VWF_rs216856 VWF_rs216873 SELE CCL2 Obtained at Initial Hospital Recruitment Biomarkers: Endothelin - 1 (pg/ml) se-selectin (ng/ml) MCP-1 (pg/ml) HS-CRP (mg/l) NT-ProBNP (ng/ml) IL-6 (pg/ml) *Electronic Health Record Page 7 BiobankVariableList.xlsx

Please check the requested variables:, and/or. Sample Information: Sample Type Buffycoat DNA Plasma Red Blood Cell (RBCs) Peripheral Blood Mononuclear Cells (PBMCs) Serum Urine UTHEALTH HOUSTON CCTS BIOBANK VARIABLE LIST Obtained at Initial Hospital Recruitment Survey: Beck Depression Inventory - II (Requires additional approval) Beck Depression Inventory - II 2Week (Requires additional approval) *Electronic Health Record Page 8 BiobankVariableList.xlsx